<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00106743</url>
  </required_header>
  <id_info>
    <org_study_id>050096</org_study_id>
    <secondary_id>05-EI-0096</secondary_id>
    <nct_id>NCT00106743</nct_id>
  </id_info>
  <brief_title>Natural History and Genetic Studies of Usher Syndrome</brief_title>
  <official_title>Natural History and Genetic Studies of Usher Syndrome</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Eye Institute (NEI)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Institutes of Health Clinical Center (CC)</source>
  <brief_summary>
    <textblock>
      This study will explore clinical and genetic aspects of Usher syndrome, an inherited disease&#xD;
      causing deafness or impaired hearing, visual problems, and, in some cases, unsteadiness or&#xD;
      balance problems. Patients with type 1 Usher syndrome usually are deaf from birth and have&#xD;
      speech and balance problems. Patients with type 2 disease generally are hearing impaired but&#xD;
      have no balance problems. Patients with type 3 disease have progressive hearing loss and&#xD;
      balance problems. All patients develop retinitis pigmentosa, an eye disease that causes poor&#xD;
      night vision and eventually, blindness.&#xD;
&#xD;
      Patients of any age with Usher syndrome may be eligible for this study. Patients who have had&#xD;
      eye and hearing evaluations are asked to send their medical records to the research team at&#xD;
      the National Eye Institute (NEI) for review. They are also asked to have a blood sample drawn&#xD;
      by a medical professional and sent to NEI for genetic analysis. Finally, they are interviewed&#xD;
      about their family histories, particularly about other relative with eye disease. Patients&#xD;
      who have not been evaluated previously have the following tests and procedures at NIH:&#xD;
&#xD;
        -  Family medical history, especially regarding eye disease. A family tree is drawn.&#xD;
&#xD;
        -  Blood draw for genetic studies of Usher syndrome.&#xD;
&#xD;
        -  Eye examination to assess visual acuity and eye pressure, and to examine pupils, lens,&#xD;
           retina, and eye movements.&#xD;
&#xD;
        -  Electroretinogram (ERG) to test the function of visual cells. Wearing eye patches, the&#xD;
           patient sits in a dark room for 30 minutes. Electrodes are taped to the forehead and the&#xD;
           eye patches are removed. The surface of the eye is numbed with eye drops and contact&#xD;
           lenses are placed on the eyes. The patient looks inside a hollow, dark globe and sees a&#xD;
           series of light flashes. Then a light is turned on inside the globe and more flashes&#xD;
           appear. The contact lenses sense small electrical signals generated by the retina when&#xD;
           the light flashes.&#xD;
&#xD;
        -  Fluorescein angiography to evaluate the eye's blood vessels. A yellow dye is injected&#xD;
           into an arm vein and travels to the blood vessels in the eyes. Pictures of the retina&#xD;
           are taken using a camera that flashes a blue light into the eye. The pictures show if&#xD;
           any dye has leaked from the vessels into the retina, indicating possible blood vessel&#xD;
           abnormality.&#xD;
&#xD;
        -  Hearing tests to help determine the patient's type of Usher syndrome. Tests to evaluate&#xD;
           hearing include examination of both ears with an otoscope, evaluation of the middle ear&#xD;
           and inner ear, and hearing tests using earphones that deliver tones and words the&#xD;
           subject listens and responds to.&#xD;
&#xD;
        -  Vestibular testing for balance function. Balance testing involves three procedures:&#xD;
&#xD;
      Videonystagmography: This test records eye movements with little cameras. First the patient&#xD;
      follows the movements of some small lights. Next, while wearing goggles, the patient lies on&#xD;
      an exam table and turns to the right and left. Lastly, a soft stream of air is blown into the&#xD;
      patient's ears four times, once in each ear with cool air and once in each ear with warm air.&#xD;
&#xD;
      Rotary chair test: With electrodes placed on the forehead, the patient sits in a rotary chair&#xD;
      in a dark room. Several red lights appear on the wall of the room and the patient follows the&#xD;
      lights as they move back and forth. Then the chair turns at several speeds, all slower than a&#xD;
      merry-go-round.&#xD;
&#xD;
      Vestibular evoked potential: Electrodes are placed behind the patient's ear and at the base&#xD;
      of the neck. Seated in a reclining chair and wearing earphones, the patient hears a brief&#xD;
      series of loud clicking sounds. When the sounds are on, the patient is asked to lift his or&#xD;
      her head up a few inches from the chair. The electrodes record information from the muscles&#xD;
      in the neck as the sounds enter the ear.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Background and objectives:&#xD;
&#xD;
      The Usher syndromes are a group of clinically variable and genetically heterogeneous&#xD;
      autosomal recessive syndromes. On the basis of clinical findings, at least three types exist.&#xD;
      Patients with Usher type I are born deaf, have vestibular problems, and are thought to&#xD;
      perceive night blindness in early childhood. Patients with Usher type II are born with a&#xD;
      hearing deficit but are able to develop intelligible speech, do not have balance problems;&#xD;
      night vision problems, and visual field changes are noted later. Patients with Usher type III&#xD;
      are born with relatively good hearing that deteriorates over a decade or more; they can have&#xD;
      progressive balance problems and they report night blindness in childhood or teens. Seven&#xD;
      genes have been mapped so far for Usher type I while five of these genes have been&#xD;
      identified. For Usher type II, four genes have been mapped and three of these have been&#xD;
      identified while there is one cloned gene for Usher type III. Quite a lot of information is&#xD;
      still unknown regarding the genetic nature of this syndrome. The picture of the three&#xD;
      clinical types of Usher syndrome has also not been well studied up to this point and cross&#xD;
      sectional studies seems to be the only source of the information available so far, regarding&#xD;
      the natural history of the disease. The aim of this protocol is to better study the natural&#xD;
      history of the disease and also make specific genotype-phenotype correlations.&#xD;
&#xD;
      Study population:&#xD;
&#xD;
      A total of 200 participants, including patients affected with all three clinical types of&#xD;
      Usher syndrome and up to 200 unaffected relatives will be enrolled to the protocol.&#xD;
      Unaffected family members, primarily parents and siblings will be enrolled to provide a blood&#xD;
      sample when considered helpful for linkage analysis. Family members will be considered&#xD;
      unaffected if they have had a previous normal examination and they don t have any symptoms of&#xD;
      decreased night or peripheral vision.&#xD;
&#xD;
      Methods:&#xD;
&#xD;
      Participants will undergo ophthalmologic, audiologic and vestibular evaluation in order to be&#xD;
      clinically characterized. Blood will be obtained by all participating subjects for the&#xD;
      molecular studies. Patients who cannot come to NIH or a collaborating Institution for&#xD;
      participation will be asked to provide a blood sample for genotyping and a copy of their&#xD;
      ophthalmologic, audiology and vestibular records, to classify phenotype. Each off-site&#xD;
      participant will be consented over the phone by an NEI investigator. All participants will be&#xD;
      requested to fill out a questionnaire.&#xD;
&#xD;
      Outcome measures:&#xD;
&#xD;
      Affected participants will be phenotypically categorized in one of the three clinical types&#xD;
      based on audiology and vestibular findings&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>March 21, 2005</start_date>
  <completion_date>April 30, 2019</completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>The primary outcomes of interest are the probands genotype and phenotype.</measure>
    <time_frame>1 year</time_frame>
  </primary_outcome>
  <enrollment type="Actual">249</enrollment>
  <condition>Retinitis Pigmentosa Syndromic</condition>
  <condition>Congenital Deafness</condition>
  <condition>Usher Syndrome</condition>
  <condition>Retinitis Pigmentosa and Deafness</condition>
  <condition>Retinitis Pigmentosa</condition>
  <eligibility>
    <criteria>
      <textblock>
        -  INCLUSION CRITERIA:&#xD;
&#xD;
        Eligible participants must:&#xD;
&#xD;
          1. have documented neurosensory hearing loss and retinitis pigmentosa and fulfill the&#xD;
             clinical characteristics for USH1, USH2 and USH3 as defined by the Usher syndrome&#xD;
             consortium. ; OR&#xD;
&#xD;
          2. be unaffected family members of a proband with Usher s syndrome, primarily parents and&#xD;
             siblings. Family members will be considered unaffected by history if they have had&#xD;
             previous normal ophthalmologic and hearing examinations and if they don't have&#xD;
             decreased night or peripheral vision.&#xD;
&#xD;
        EXCLUSION CRITERIA:&#xD;
&#xD;
        Patients will be ineligible if they:&#xD;
&#xD;
          1. had an intrauterine infection, perinatal/congenital infections, or intrauterine and&#xD;
             birth complications. These conditions can result in damage to both the auditory or&#xD;
             visual system.&#xD;
&#xD;
          2. have concurrent inherited or acquired conditions that affect the visual and/or&#xD;
             auditory system and significantly alter the phenotype.&#xD;
&#xD;
        Both affected and unaffected individuals will be ineligible if they:&#xD;
&#xD;
          1. Are unwilling or unable to provide a blood sample or unable to undergo the study&#xD;
             procedures.&#xD;
&#xD;
          2. Are younger than 2 years old.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>2 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Wadih Zein, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>National Eye Institute (NEI)</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>National Institutes of Health Clinical Center, 9000 Rockville Pike</name>
      <address>
        <city>Bethesda</city>
        <state>Maryland</state>
        <zip>20892</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Queens College of the City University of New York</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <removed_countries>
    <country>Israel</country>
  </removed_countries>
  <reference>
    <citation>Smith RJ, Berlin CI, Hejtmancik JF, Keats BJ, Kimberling WJ, Lewis RA, MÃ¶ller CG, Pelias MZ, Tranebjaerg L. Clinical diagnosis of the Usher syndromes. Usher Syndrome Consortium. Am J Med Genet. 1994 Mar 1;50(1):32-8.</citation>
    <PMID>8160750</PMID>
  </reference>
  <reference>
    <citation>Keats BJ, Corey DP. The usher syndromes. Am J Med Genet. 1999 Sep 24;89(3):158-66. Review.</citation>
    <PMID>10704190</PMID>
  </reference>
  <reference>
    <citation>Fishman GA, Kumar A, Joseph ME, Torok N, Anderson RJ. Usher's syndrome. Ophthalmic and neuro-otologic findings suggesting genetic heterogeneity. Arch Ophthalmol. 1983 Sep;101(9):1367-74.</citation>
    <PMID>6604514</PMID>
  </reference>
  <verification_date>April 30, 2019</verification_date>
  <study_first_submitted>March 29, 2005</study_first_submitted>
  <study_first_submitted_qc>March 29, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 30, 2005</study_first_posted>
  <last_update_submitted>December 11, 2019</last_update_submitted>
  <last_update_submitted_qc>December 11, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">December 12, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Usher Syndrome</keyword>
  <keyword>Retinitis Pigmentosa</keyword>
  <keyword>Congenital Deafness</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Deafness</mesh_term>
    <mesh_term>Hearing Loss</mesh_term>
    <mesh_term>Usher Syndromes</mesh_term>
    <mesh_term>Retinitis</mesh_term>
    <mesh_term>Retinitis Pigmentosa</mesh_term>
    <mesh_term>Syndrome</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

